文献速递消化道肿瘤与早癌消化内镜

Barrett食管射频消融术后循证监测间隔的制定

Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus.
PubMed 文献 · Gastroenterology · 2018-04-13

基于美国射频消融注册库(2004-2013)和英国国家Halo注册库(2007-2015)数据,构建并验证预测Barrett食管射频消融成功后再发肿瘤风险的模型,提出基于基线组织学分级的三类风险监测间隔。

要点

  • 基于最严重CEIM前组织学分级模型预测肿瘤再发的C统计量为0.892(95%CL 0.863-0.921)。
  • 低级别不典型增生患者建议CEIM后1年和3年行监测内镜。
  • 高级别不典型增生或黏膜内腺癌患者建议CEIM后0.25、0.5、1年监测,之后每年一次。

核心结论

  • 在美国RFA和英国NHR的BE数据分析中,大幅缩减的监测内镜方案可提供对侵袭性腺癌的保护。
  • 遵循推荐的监测间隔可减少内镜检查数量,同时以低于1/1000次内镜的比率识别不可切除癌症。

研究设计与样本

  • 收集美国射频消融注册库(US RFA,2004-2013)和英国国家Halo注册库(UK NHR,2007-2015)数据,构建并验证预测初始成功RFA后肿瘤再发发生率的模型。
  • 开发3类风险类别并建模,使侵袭性腺癌再发风险为0.1%。
  • 拟合Cox比例风险模型,通过C统计量和95%置信限评估区分度。

主要发现

  • 肿瘤再发发生率与CEIM前最严重组织学分级、年龄、内镜下黏膜切除术、性别和基线BE节段长度相关。
  • 多变量分析中,仅基于CEIM前最严重组织学的模型在美国RFA注册库预测肿瘤再发的C统计量为0.892(95%置信限,0.863-0.921)。
  • 该模型在英国NHR数据中也表现良好。

关键数值与推荐

  • 模型基于基线组织学分级将患者分为3个风险组:非不典型增生BE;不典型增生不确定、低级别不典型增生和高级别不典型增生;或黏膜内腺癌。
  • 对于低级别不典型增生患者,建议CEIM后1年和3年行监测内镜。
  • 对于高级别不典型增生或黏膜内腺癌患者,建议CEIM后0.25、0.5和1年行监测内镜,之后每年一次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Barrett's esophagus (BE) recurs in 25% or more of patients treated successfully with radiofrequency ablation (RFA), so surveillance endoscopy is recommended after complete eradication of intestinal metaplasia (CEIM). The frequency of surveillance is informed only by expert opinion. We aimed to model the incidence of neoplastic recurrence, validate the model in an independent cohort, and propose evidence-based surveillance intervals. METHODS: We collected data from the United States Radiofrequency Ablation Registry (US RFA, 2004-2013) and the United Kingdom National Halo Registry (UK NHR, 2007-2015) to build and validate models to predict the incidence of neoplasia recurrence after initially successful RFA. We developed 3 categories of risk and modeled intervals to yield 0.1% risk of recurrence with invasive adenocarcinoma. We fit Cox proportional hazards models assessing discrimination by C statistic and 95% confidence limits. RESULTS: The incidence of neoplastic recurrence was associated with most severe histologic grade before CEIM, age, endoscopic mucosal resection, sex, and baseline BE segment length. In multivariate analysis, a model based solely on most severe pre-CEIM histology predicted neoplastic recurrence with a C statistic of 0.892 (95% confidence limit, 0.863-0.921) in the US RFA registry. This model also performed well when we used data from the UK NHR. Our model divided patients into 3 risk groups based on baseline histologic grade: non-dysplastic BE; indefinite for dysplasia, low-grade dysplasia, and high-grade dysplasia; or intramucosal adenocarcinoma. For patients with low-grade dysplasia, we propose surveillance endoscopy at 1 and 3 years after CEIM; for patients with high-grade dysplasia or intramucosal adenocarcinoma, we propose surveillance endoscopy at 0.25, 0.5, and 1 year after CEIM, then annually. CONCLUSION: In analyses of data from the US RFA and UK NHR for BE, a much-attenuated schedule of surveillance endoscopy would provide protection from invasive adenocarcinoma. Adherence to the recommended surveillance intervals could decrease the number of endoscopies performed yet identify unresectable cancers at rates less than 1/1000 endoscopies.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Cotton CC, Haidry R, Thrift AP, et al. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology. 2018. PMID: 29655833. doi:10.1053/j.gastro.2018.04.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。